The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Serotonin-Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise
Open accessAbstract
The precise mechanisms of pain perception and transmission in the central nervous system have not been fully elucidated. However, extensive data support a role for the monoamine neurotransmitters, serotonin and norepinephrine, in the modulation of pain. Experiments with animal models of pain indicate that noradrenergic interventions, and to a lesser extent serotonergic interventions, reduce pain-related behavior. This is supported by data from clinical trials in humans in which antidepressants have been shown to reduce pain and functional impairment in central and neuropathic pain conditions. These effects are particularly well-studied in trials with serotonin-norepinephrine reuptake inhibitors (SNRIs), which have provided a useful tool in the clinician's arsenal, particularly considering the limitations of other classes of pain medications such as opioids, anti-inflammatories, and anticonvulsants (i.e., limited efficacy, safety and tolerability issues). Moreover, painful physical symptoms are frequently comorbid with major psychiatric disorders such as major depressive disorder and anxiety disorders. This paper reviewed and summarized the rationale and potential role of SNRIs for the control of pain including clinical and preclinical background. Currently evidence does not definitely support a role of the SNRIs, while limited data propose a putative promise of SNRIs in the treatment of pain related disorders including fibromyalgia and depressed patients with multiple somatic complaints. More researches are warranted to generalize currently available preliminary evidences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurocognitive aspects of pain perception
Wiech, K., Ploner, M., & Tracey, I. (2008) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2008.05.005 · Cited by 737
Arnold, L. M., Lu, Y., Crofford, L. J., Wohlreich, M., Detke, M. J., Iyengar, S., & Goldstein, D. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20485 · Cited by 624 · cited 1×
“Duloxetine has demonstrated efficacy in the treatment of fibromyalgia in two similarly designed pivotal randomized, double-blind, placebo-controlled clinical trials (RCTs) [1, 3], and it has become the first antidepressant medication to obtain US FDA approval for this indication.”
Arnold, L. M., Rosen, A., Pritchett, Y. L., D'Souza, D. N., Goldstein, D. J., Iyengar, S., & Wernicke, J. F. (2005) · Pain · doi:10.1016/j.pain.2005.06.031 · Cited by 471
Treatment of fibromyalgia with antidepressants: A meta-analysis
O’Malley, P. G., Balden, E., Tomkins, G., Santoro, J., Kroenke, K., & Jackson, J. L. (2000) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2000.06279.x · Cited by 340
Treatment of Fibromyalgia Syndrome With Antidepressants: A Meta-analysis
Häuser, W., Bernardy, K., Üçeyler, N., & Sommer, C. (2009) · JAMA · doi:10.1001/jama.2008.944 · Cited by 338
Wiech, K., Kalisch, R., Weiskopf, N., Pleger, B., Stephan, K. E., & Dolan, R. J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2568-06.2006 · Cited by 323
Fales, C. L., Barch, D. M., Rundle, M. M., Mintun, M. A., Mathews, J., Snyder, A. Z., & Sheline, Y. I. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.04.027 · Cited by 266
Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity
Vaishnavi, S. N., Nemeroff, C. B., Plott, S. J., Rao, S. G., Kranzler, J., & Owens, M. J. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.07.006 · Cited by 178
Venlafaxine treatment of fibromyalgia
Sayar, K., Aksu, G., Ak, I., & Tosun, M. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1d112 · Cited by 157
Cited by
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Transition from acute to chronic pain after surgery
Glare, P., Aubrey, K. R., & Myles, P. S. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30352-6 · Cited by 914
Sleep deficiency and chronic pain: potential underlying mechanisms and clinical implications
Haack, M., Simpson, N., Sethna, N., Kaur, S., & Mullington, J. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0439-z · Cited by 641
Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets
Dewanjee, S., Das, S., Das, A. K., Bhattacharjee, N., Dihingia, A., Dua, T. K., Kalita, J., & Manna, P. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.034 · Cited by 300
Amin, B., & Hosseinzadeh, H. (2015) · Planta Medica · doi:10.1055/s-0035-1557838 · Cited by 276
Metadata
- Authors
- Marks, D., Shah, M., Patkar, A., Masand, P., Park, G.-Y., & Pae, C.-U.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-12-01
- Volume
- 7
- Issue
- 4
- Pages
- 331-336
- ISSN
- 1570-159X (ISSN-L)
- OpenAlex
- W1970125541
- Cited by
- 236
- References
- 9
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serotonin-Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise. https://app.cochat.ai/papers/10.2174/157015909790031201
- The paper
- Marks, D., Shah, M., Patkar, A., Masand, P., Park, G.-Y., & Pae, C.-U. (2009). Serotonin-Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise. Current Neuropharmacology. https://doi.org/10.2174/157015909790031201
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.